Compare TCX & TARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TCX | TARA |
|---|---|---|
| Founded | 1992 | N/A |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 167.0M | 159.6M |
| IPO Year | 2005 | 2014 |
| Metric | TCX | TARA |
|---|---|---|
| Price | $11.93 | $2.13 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $25.71 |
| AVG Volume (30 Days) | 88.2K | ★ 960.8K |
| Earning Date | 11-05-2026 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.25 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $362,275,000.00 | $2,948,000.00 |
| Revenue This Year | $26.83 | N/A |
| Revenue Next Year | $10.04 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 6.76 | N/A |
| 52 Week Low | $8.45 | $2.28 |
| 52 Week High | $25.17 | $7.82 |
| Indicator | TCX | TARA |
|---|---|---|
| Relative Strength Index (RSI) | 65.37 | 33.70 |
| Support Level | $8.82 | $2.28 |
| Resistance Level | $14.76 | $4.13 |
| Average True Range (ATR) | 1.05 | 0.15 |
| MACD | 0.26 | 0.04 |
| Stochastic Oscillator | 81.57 | 20.29 |
Tucows Inc is a corporate parent, allocating capital and providing efficient shared services to its three businesses. The Company offers Mobile Service Enabler (MSE) solutions, as well as professional services to other retail mobile providers. The Company is also a distributor of Internet services, including domain name registration, digital certificates, and email. It provides these services through an Internet-based distribution network of Internet Service Providers, web hosting companies, and other providers of Internet services to end-users. It operates in three segments: Ting, Wavelo, and Tucows Domains. It generates the majority of its revenue from Tucows Domains. The company generates key revenue from Canada and USA.
Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.